# Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention

> **NCT04520620** · PHASE4 · WITHDRAWN · sponsor: **Centre Hospitalier Universitaire de Saint Etienne**

## Conditions studied

- Sars-CoV2

## Interventions

- **DRUG:** Lovenox 40 MG in 0.4 mL Prefilled Syringe
- **DEVICE:** Ultrasound of the lower limbs

## Key facts

- **NCT ID:** NCT04520620
- **Lead sponsor:** Centre Hospitalier Universitaire de Saint Etienne
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-05-02
- **Primary completion:** 2020-07-10
- **Final completion:** 2020-07-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** End of the COVID 19 epidemic in the region and decision to participate in a national study on the same subject (COVI-DOSE).
- **Last updated:** 2020-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04520620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04520620, "Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04520620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*